Structural Optimization of Oxaprozin for Selective Inverse Nurr1 Agonism.


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
30 Jul 2024
Historique:
medline: 31 7 2024
pubmed: 31 7 2024
entrez: 31 7 2024
Statut: aheadofprint

Résumé

Nuclear receptor related 1 (Nurr1, NR4A2) is a ligand-sensing transcription factor with neuroprotective and anti-inflammatory roles widely distributed in the CNS. Pharmacological Nurr1 modulation is considered a promising experimental strategy in Parkinson's and Alzheimer's disease but target validation is incomplete. While significant progress has been made in Nurr1 agonist development, inverse agonists blocking the receptor's constitutive activity are lacking. Here we report comprehensive structure-activity relationship elucidation of oxaprozin which acts as moderately potent and nonselective inverse Nurr1 agonist and RXR agonist. We identified structural determinants selectively driving RXR agonism or inverse Nurr1 agonism of the scaffold enabling the development of selective inverse Nurr1 agonists with enhanced potency and strong efficacy.

Identifiants

pubmed: 39081058
doi: 10.1021/acs.jmedchem.4c01218
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Sabine Willems (S)

Department of Pharmacy, Ludwig-Maximilians-Universität München, 81377 Munich, Germany.

Romy Busch (R)

Department of Pharmacy, Ludwig-Maximilians-Universität München, 81377 Munich, Germany.

Felix Nawa (F)

Department of Pharmacy, Ludwig-Maximilians-Universität München, 81377 Munich, Germany.

Marco Ballarotto (M)

Department of Pharmacy, Ludwig-Maximilians-Universität München, 81377 Munich, Germany.
Department of Pharmaceutical Sciences, Università degli Studi di Perugia, 06123 Perugia, Italy.

Felix F Lillich (FF)

Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, 60438 Frankfurt, Germany.
Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, 60596 Frankfurt, Germany.

Till Kasch (T)

Department of Pharmacy, Ludwig-Maximilians-Universität München, 81377 Munich, Germany.

Úrsula López-García (Ú)

Department of Pharmacy, Ludwig-Maximilians-Universität München, 81377 Munich, Germany.

Julian A Marschner (JA)

Department of Pharmacy, Ludwig-Maximilians-Universität München, 81377 Munich, Germany.

Lorena A Rüger (LA)

Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, 60438 Frankfurt, Germany.

Beatrice Renelt (B)

Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, 60438 Frankfurt, Germany.

Julia Ohrndorf (J)

Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, 60438 Frankfurt, Germany.

Silvia Arifi (S)

Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, 60438 Frankfurt, Germany.

Daniel Zaienne (D)

Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, 60438 Frankfurt, Germany.

Ewgenij Proschak (E)

Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, 60438 Frankfurt, Germany.
Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, 60596 Frankfurt, Germany.

Jörg Pabel (J)

Department of Pharmacy, Ludwig-Maximilians-Universität München, 81377 Munich, Germany.

Daniel Merk (D)

Department of Pharmacy, Ludwig-Maximilians-Universität München, 81377 Munich, Germany.
Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, 60438 Frankfurt, Germany.

Classifications MeSH